SecBot SecBot

DGX

QUEST DIAGNOSTICS INC
NYSE· Services-Medical Laboratories· Inc. DE· CIK 0001022079 Healthcare & Medical Devices
$261.70 +2.10 (+0.81%)
Nov 16 4:00 PM ET · prev $259.60
Market cap
$28.6B
Large cap
Consensus
Buy
52% Buy or better · 23 analysts
Median target
$260.00
−1% · range $235.00–279.00
1 year
+40.6%
from $186.19 · Nov 17
30 days
+11.4%
from $235.00
52-week range
$173.49–261.70
at the high
Avg volume 20D
942.6K
shares / day
Short interest
3.73M
≈3.4% of shares · +4.5%
Days to cover
3.6
at average volume
Insider net
−$20.7M
0 buyers · 7 sellers · since May 20
New fund stakes
2
Q2 2026 13F · 0 exits
Reddit crowd
60°
Warm · 6 mentions this week
SecBot read MIXED 16 reports · 90 days
Balance 0 bearish · 2 bullish · 1 mixed · 13 neutral oldest → newest, height = score
Avg score ·High conf. 11/16

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    7 insiders sold $20.7M.

  • InstitutionsBULLISH

    Q2 2026: 44 added (2 new), 24 trimmed or exited. Largest new: Pfa Pension, Forsikringsaktieselskab $43.6M, Adage Capital Partners Gp, L.L.C $22.5M.

  • AnalystsBULLISH

    12 of 23 rate it Buy or better. Median target $260.00 (−1%).

  • Short sellersSTEADY

    Short interest +4.5% to 3.73M shares. 3.6 days to cover, ≈3.4% of shares.

  • TrendUPTREND

    8% above its 50-day average. New closing high $261.70 on Nov 16.

  • SocialQUIET

    Crowd 60° (warm) this week from 6 mentions: 2 bullish, 0 bearish. No setup is alerting.

Who's buying

13F· Q2 2026
2
new positions
0
exits
$66.1M
in new stakes
FundMoveSharesValue
FMR LLCADD1,398,735$296.5M
GOLDMAN SACHS GROUP INCTRIM982,694$208.3M
UBS Group AGADD888,906$188.4M
SCHRODER INVESTMENT MANAGEMENT GROUPADD417,715$88.8M
BNP PARIBAS FINANCIAL MARKETSADD395,245$83.8M
Qube Research & Technologies LtdTRIM343,398$72.8M
MACKENZIE FINANCIAL CORPDOUBLED333,295$70.6M
BALYASNY ASSET MANAGEMENT L.P.DOUBLED275,371$58.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

23 analysts
Buy 52% rate it Buy or better
Strong Buy6Buy6Hold11Sell0Strong Sell0
12-month targets · 15 analysts

Price is inside the target range. Median implies −1%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Oct 7, 2026Barclays
MAINTAIN
MAINTAINOverweight
Sep 21, 2026Truist Securities
MAINTAIN
MAINTAINHold
Sep 8, 2026UBS
MAINTAIN
MAINTAINNeutral
Jul 28, 2026JP Morgan
MAINTAIN
MAINTAINNeutral
Jul 24, 2026UBS
MAINTAIN
MAINTAINNeutral
Jul 24, 2026Mizuho
MAINTAIN
MAINTAINOutperform
Congressional trades
DGX trades disclosed by members of Congress, with disclosure delay.
4 members · 3 buys / 3 sells
DateMemberType AmountDisclosed
Oct 7, 2026 Ro KhannaDHouse Spouse account · Quest Diagnostics Inc SELL $1K–$15K Nov 5, 2026 +29d
Sep 4, 2026 Ro KhannaDHouse Spouse account · Quest Diagnostics Inc BUY $1K–$15K Oct 7, 2026 +33d
Mar 27, 2026 Alan ArmstrongRSenate Joint account · Quest Diagnostics Inc BUY $1K–$15K Jul 21, 2026 +116d
Oct 30, 2025 Julie JohnsonDHouse Joint account · Quest Diagnostics Inc BUY $1K–$15K Aug 5, 2026 +279d
Oct 30, 2025 Julie JohnsonDHouse Joint account · Quest Diagnostics Inc SELL $1K–$15K Aug 5, 2026 +279d
Mar 10, 2025 Carol MillerRHouse Spouse account · Quest Diagnostics Inc SELL $15K–$50K Aug 13, 2026 +521d

Insider ledger

Form 4
$0
bought · 0 insiders
$20.7M
sold · 7 insiders
DateInsiderTypeValue
Nov 9, 2026
Plewman Patrick
SVP for Diagnostic Services
Nov 9, 2026
EXERCISE$545.9K
Nov 9, 2026
Plewman Patrick
SVP for Diagnostic Services
Nov 9, 2026
SELL$1.1M
Nov 9, 2026
Plewman Patrick
SVP for Diagnostic Services
Nov 9, 2026
SELL$1.7M
Nov 9, 2026
Plewman Patrick
SVP for Diagnostic Services
Nov 9, 2026
SELL$167.3K
Nov 9, 2026
Plewman Patrick
SVP for Diagnostic Services
Nov 9, 2026
EXERCISE$868.2K
Nov 3, 2026
DELANEY MARK E
SVP & Chief Commercial Officer
Nov 3, 2026
AWARD2,615 sh
Nov 3, 2026
Doherty Catherine T.
Executive Vice President
Nov 3, 2026
AWARD4,827 sh
Nov 3, 2026
Doherty Catherine T.
Executive Vice President
Nov 3, 2026
EXERCISE$2.7M

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 12, 2026 SEC
Two DGX insiders (SVP Plewman and EVP Doherty) sold a combined $2.57M in open-market sales, both under 10b5-1 plans…
CLUSTER · Impact 2/10
Nov 10, 2026 Press
Quest Diagnostics declared a quarterly cash dividend of $0.86 per share, payable on January 27, 2027 to shareholders…
Impact 2/10
Nov 10, 2026 Dividend
Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J., Nov. 10, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of d
Nov 10, 2026 SEC
State Street Corp disclosed a passive 5.0% stake in Quest Diagnostics as of September 30, 2026, holding approximately…
SC 13G · Impact 3/10
Nov 9, 2026 SEC
Quest Diagnostics announced CFO Sam Samad will participate in a fireside chat at a healthcare conference on December…
PRESS-RELEASE · Impact 2/10
Nov 9, 2026 Insider
Plewman Patrick acquired via exercise 4,274 shares
SVP for Diagnostic Services @ $127.73 ($545.9K)
Nov 9, 2026 Insider
Plewman Patrick sold 4,274 shares
SVP for Diagnostic Services @ $257.34 ($1.1M)
Nov 9, 2026 Insider
Plewman Patrick sold 6,793 shares
SVP for Diagnostic Services @ $257.34 ($1.7M)

Short side

FINRA· Oct 30, 2026
3,734,103
shares short
+4.5%
vs prior settlement
3.6
days to cover
≈3.4%
of shares outstanding
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Reddit Mentions per day, 14 days
Crowd this week 60° Warm 2 bullish · 0 bearish
Mentions, 7 days 6 0 in posts · 6 in comments
Recent comments
All social signals and their track records

Washington

Corporate Lobbying

34 lobbying filings and 12 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

SecBot reports

22 filings · 1 press release · 4 bullish · 1 bearish · 1 mixed · 16 neutral
All DGX filing & press-release reports (23)